1266 related articles for article (PubMed ID: 16322337)
1. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
2. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
3. Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors.
Festuccia C; Gravina GL; Muzi P; Millimaggi D; Dolo V; Vicentini C; Bologna M
Prostate; 2008 Jun; 68(9):965-74. PubMed ID: 18361408
[TBL] [Abstract][Full Text] [Related]
4. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
5. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
6. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Wu Z; Gioeli D; Conaway M; Weber MJ; Theodorescu D
Prostate; 2008 Jun; 68(9):935-44. PubMed ID: 18386291
[TBL] [Abstract][Full Text] [Related]
7. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer.
Li P; Zhang Q; Torossian A; Li ZB; Xu WC; Lu B; Fu S
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e391-7. PubMed ID: 22414288
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Noro R; Gemma A; Kosaihira S; Kokubo Y; Chen M; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Kudoh S
BMC Cancer; 2006 Dec; 6():277. PubMed ID: 17150102
[TBL] [Abstract][Full Text] [Related]
10. Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Qin B; Ariyama H; Baba E; Tanaka R; Kusaba H; Harada M; Nakano S
Cancer Chemother Pharmacol; 2006 Nov; 58(5):577-84. PubMed ID: 16532343
[TBL] [Abstract][Full Text] [Related]
11. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
12. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Kassouf W; Dinney CP; Brown G; McConkey DJ; Diehl AJ; Bar-Eli M; Adam L
Cancer Res; 2005 Nov; 65(22):10524-35. PubMed ID: 16288045
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
14. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Kokubo Y; Gemma A; Noro R; Seike M; Kataoka K; Matsuda K; Okano T; Minegishi Y; Yoshimura A; Shibuya M; Kudoh S
Br J Cancer; 2005 May; 92(9):1711-9. PubMed ID: 15870831
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Dominguez-Escrig JL; Kelly JD; Neal DE; King SM; Davies BR
Clin Cancer Res; 2004 Jul; 10(14):4874-84. PubMed ID: 15269164
[TBL] [Abstract][Full Text] [Related]
16. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
[TBL] [Abstract][Full Text] [Related]
17. Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Xing WJ; Zou Y; Han QL; Dong YC; Deng ZL; Lv XH; Jiang T; Ren H
Clin Exp Pharmacol Physiol; 2013 Jan; 40(1):13-21. PubMed ID: 23110505
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
Shrader M; Pino MS; Lashinger L; Bar-Eli M; Adam L; Dinney CP; McConkey DJ
Cancer Res; 2007 Feb; 67(4):1430-5. PubMed ID: 17308080
[TBL] [Abstract][Full Text] [Related]
19. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
20. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]